NASDAQ:MNLO - Menlo Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $6.73 -0.02 (-0.30 %) (As of 05/26/2019 01:12 PM ET)Previous Close$6.73Today's Range$6.60 - $6.9152-Week Range$3.74 - $12.00Volume18,122 shsAverage Volume81,072 shsMarket Capitalization$161.09 millionP/E RatioN/ADividend YieldN/ABeta3.38 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Menlo Therapeutics Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis; psoriasis; chronic pruritus; atopic dermatitis; and refractory chronic cough. The company was formerly known as Tigercat Pharma, Inc. and changed its name to Menlo Therapeutics Inc. in May 2016. Menlo Therapeutics Inc. was founded in 2011 and is headquartered in Redwood City, California. Receive MNLO News and Ratings via Email Sign-up to receive the latest news and ratings for MNLO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MNLO Previous Symbol CUSIPN/A CIK1566044 Webhttp://www.menlotherapeutics.com/ Phone650-486-1416Debt Debt-to-Equity RatioN/A Current Ratio11.78 Quick Ratio11.78Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$10.64 million Price / Sales15.14 Cash FlowN/A Price / Cash FlowN/A Book Value$4.83 per share Price / Book1.39Profitability EPS (Most Recent Fiscal Year)($2.37) Net Income$-51,440,000.00 Net MarginsN/A Return on Equity-41.85% Return on Assets-39.22%Miscellaneous Employees43 Outstanding Shares23,936,000Market Cap$161.09 million Next Earnings Date8/7/2019 (Estimated) OptionableNot Optionable Menlo Therapeutics (NASDAQ:MNLO) Frequently Asked Questions What is Menlo Therapeutics' stock symbol? Menlo Therapeutics trades on the NASDAQ under the ticker symbol "MNLO." How were Menlo Therapeutics' earnings last quarter? Menlo Therapeutics Inc (NASDAQ:MNLO) posted its quarterly earnings results on Thursday, May, 2nd. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.81) by $0.00. View Menlo Therapeutics' Earnings History. When is Menlo Therapeutics' next earnings date? Menlo Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August 7th 2019. View Earnings Estimates for Menlo Therapeutics. What price target have analysts set for MNLO? 4 analysts have issued twelve-month price objectives for Menlo Therapeutics' shares. Their forecasts range from $7.00 to $29.00. On average, they expect Menlo Therapeutics' stock price to reach $20.3333 in the next year. This suggests a possible upside of 202.1% from the stock's current price. View Analyst Price Targets for Menlo Therapeutics. What is the consensus analysts' recommendation for Menlo Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Menlo Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Menlo Therapeutics. What are Wall Street analysts saying about Menlo Therapeutics stock? Here are some recent quotes from research analysts about Menlo Therapeutics stock: 1. According to Zacks Investment Research, "Menlo Therapeutics Inc. is a late stage biopharmaceutical company. It focused on the development of serlopitant and treatment of chronic itch and chronic refractory cough. The company's product pipeline consists of Prurigo Nodularis Itch, Atopic Dermatitis Itch, Psoriasis Itch and Refractory Chronic Cough which are in clinical stage. Menlo Therapeutics Inc. is headquartered in Redwood City, California. " (5/18/2019) 2. Cantor Fitzgerald analysts commented, ". After a solid quarter of execution in 1Q19, we reiterate our OW rating and 12-month price target of $25 for MNLO shares. We continue to believe that upward earnings revisions and multiple expansion will drive the stock higher. A greater appreciation for the company’s multiple indication approach for serlopitant will increase earnings estimates to levels not yet reflected in FactSet consensus expectations, in our view." (5/2/2019) Has Menlo Therapeutics been receiving favorable news coverage? News stories about MNLO stock have been trending negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Menlo Therapeutics earned a coverage optimism score of -2.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 8.0 out of 10, meaning that recent media coverage is very likely to have an effect on the stock's share price in the immediate future. Who are some of Menlo Therapeutics' key competitors? Some companies that are related to Menlo Therapeutics include Advanz Pharma (CXRXF), TG Therapeutics (TGTX), Organogenesis (ORGO), Lexicon Pharmaceuticals (LXRX), Crinetics Pharmaceuticals (CRNX), Aurinia Pharmaceuticals (AUPH), Akebia Therapeutics (AKBA), Viking Therapeutics (VKTX), CannTrust (CTST), Odonate Therapeutics (ODT), Puma Biotechnology (PBYI), OvaScience (OVAS), Obseva (OBSV), Magenta Therapeutics (MGTA) and Zymeworks (ZYME). What other stocks do shareholders of Menlo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Menlo Therapeutics investors own include Allena Pharmaceuticals (ALNA), Synergy Pharmaceuticals (SGYP), DelMar Pharmaceuticals (DMPI), Amicus Therapeutics (FOLD), Iovance Biotherapeutics (IOVA), Rigel Pharmaceuticals (RIGL), Spero Therapeutics (SPRO), Fate Therapeutics (FATE), Tetraphase Pharmaceuticals (TTPH) and TherapeuticsMD (TXMD). Who are Menlo Therapeutics' key executives? Menlo Therapeutics' management team includes the folowing people: Mr. Steven L. Basta, Pres, CEO & Director (Age 53)Ms. Kristine M. Ball CPA, Sr. VP of Corp. Strategy & CFO (Age 47)Dr. Mary C. Spellman, Chief Medical Officer (Age 57)Dr. Paul S. Kwon M.D., Chief Scientific Officer (Age 48)Mr. Stuart D. Sedlack M.B.A., VP of Bus. Devel. (Age 54) When did Menlo Therapeutics IPO? (MNLO) raised $86 million in an IPO on Thursday, January 25th 2018. The company issued 5,700,000 shares at $14.00-$16.00 per share. Jefferies, Piper Jaffray and Guggenheim Securities acted as the underwriters for the IPO and JMP Securities was co-manager. Who are Menlo Therapeutics' major shareholders? Menlo Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include First Manhattan Co. (9.70%), venBio Partners LLC (6.11%), Janus Henderson Group PLC (6.26%), BlackRock Inc. (2.64%), JPMorgan Chase & Co. (2.71%) and Jacobs Levy Equity Management Inc. (0.44%). Company insiders that own Menlo Therapeutics stock include Presidio Partners 2007 Gp, LP and Vivo Capital Surplus Fund Viii. View Institutional Ownership Trends for Menlo Therapeutics. Which institutional investors are selling Menlo Therapeutics stock? MNLO stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Alambic Investment Management L.P., JPMorgan Chase & Co. and Morgan Stanley. View Insider Buying and Selling for Menlo Therapeutics. Which institutional investors are buying Menlo Therapeutics stock? MNLO stock was purchased by a variety of institutional investors in the last quarter, including venBio Partners LLC, First Manhattan Co., BlackRock Inc., Oxford Asset Management LLP, Renaissance Technologies LLC, Parametric Portfolio Associates LLC, State of Wisconsin Investment Board and Jacobs Levy Equity Management Inc.. View Insider Buying and Selling for Menlo Therapeutics. How do I buy shares of Menlo Therapeutics? Shares of MNLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Menlo Therapeutics' stock price today? One share of MNLO stock can currently be purchased for approximately $6.73. How big of a company is Menlo Therapeutics? Menlo Therapeutics has a market capitalization of $161.09 million and generates $10.64 million in revenue each year. The company earns $-51,440,000.00 in net income (profit) each year or ($2.37) on an earnings per share basis. Menlo Therapeutics employs 43 workers across the globe. What is Menlo Therapeutics' official website? The official website for Menlo Therapeutics is http://www.menlotherapeutics.com/. How can I contact Menlo Therapeutics? Menlo Therapeutics' mailing address is 200 CARDINAL WAY 2ND FLOOR, REDWOOD CITY CA, 94063. The company can be reached via phone at 650-486-1416 or via email at [email protected] MarketBeat Community Rating for Menlo Therapeutics (NASDAQ MNLO)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 75 (Vote Outperform)Underperform Votes: 99 (Vote Underperform)Total Votes: 174MarketBeat's community ratings are surveys of what our community members think about Menlo Therapeutics and other stocks. Vote "Outperform" if you believe MNLO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNLO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/26/2019 by MarketBeat.com StaffFeatured Article: What is net income? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.